Enliven Common Stock Shares Outstanding vs Current Deferred Revenue Analysis

ELVN Stock

21.68 0.18 0.84%

Enliven Therapeutics financial indicator trend analysis is much more than just examining Enliven Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Enliven Therapeutics is a good investment. Please check the relationship between Enliven Therapeutics Common Stock Shares Outstanding and its Current Deferred Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.

Common Stock Shares Outstanding vs Current Deferred Revenue

Common Stock Shares Outstanding vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Enliven Therapeutics Common Stock Shares Outstanding account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Enliven Therapeutics' Common Stock Shares Outstanding and Current Deferred Revenue is 0.75. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Enliven Therapeutics, assuming nothing else is changed. The correlation between historical values of Enliven Therapeutics' Common Stock Shares Outstanding and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Enliven Therapeutics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Common Stock Shares Outstanding i.e., Enliven Therapeutics' Common Stock Shares Outstanding and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.75

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Enliven Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Enliven Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.At this time, Enliven Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 17th of February 2025, Enterprise Value is likely to grow to about 370.6 M, while Issuance Of Capital Stock is likely to drop about 505.3 K.

	2022	2023	2024	2025 (projected)
Net Interest Income	1.1M	12.0M	13.8M	14.5M
Cost Of Revenue	622K	297K	341.6K	252.6K

Net Interest Income Cost Of Revenue

Enliven Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Short Term Investments	Other Liab	Net Tangible Assets	Current Deferred Revenue	Capital Lease Obligations	Net Invested Capital
Total Assets		-0.49	0.96	0.96	0.91	-0.79	-0.92	0.04	0.77	1.0	0.95	0.08	0.94	0.94	0.27	1.0	0.92	0.69	0.61	0.55	0.95	-0.75	-0.78	0.79	0.83	0.91
Short Long Term Debt Total	-0.49		-0.35	-0.4	-0.21	0.64	0.45	-0.52	-0.62	-0.5	-0.31	-0.54	-0.31	-0.29	-0.56	-0.49	-0.25	-0.4	-0.11	-0.02	-0.32	0.25	0.46	-0.38	-0.35	-0.25
Other Current Liab	0.96	-0.35		1.0	0.96	-0.59	-0.96	-0.05	0.58	0.95	0.99	-0.16	1.0	0.99	0.03	0.96	0.98	0.68	0.74	0.71	0.97	-0.79	-0.74	0.8	0.85	0.97
Total Current Liabilities	0.96	-0.4	1.0		0.94	-0.62	-0.97	0.03	0.61	0.96	0.98	-0.09	0.99	0.98	0.1	0.96	0.96	0.73	0.76	0.72	0.95	-0.78	-0.79	0.83	0.88	0.94
Total Stockholder Equity	0.91	-0.21	0.96	0.94		-0.49	-0.86	-0.31	0.48	0.9	0.98	-0.33	0.98	0.99	-0.15	0.91	0.99	0.48	0.62	0.63	0.99	-0.78	-0.57	0.65	0.72	1.0
Net Debt	-0.79	0.64	-0.59	-0.62	-0.49		0.62	-0.37	-0.98	-0.8	-0.57	-0.63	-0.55	-0.54	-0.76	-0.79	-0.49	-0.66	-0.29	-0.16	-0.58	0.39	0.76	-0.67	-0.63	-0.49
Retained Earnings	-0.92	0.45	-0.96	-0.97	-0.86	0.62		-0.16	-0.61	-0.91	-0.93	0.04	-0.94	-0.92	-0.15	-0.91	-0.9	-0.79	-0.82	-0.78	-0.88	0.63	0.83	-0.89	-0.92	-0.88
Accounts Payable	0.04	-0.52	-0.05	0.03	-0.31	-0.37	-0.16		0.36	0.04	-0.13	0.76	-0.11	-0.18	0.76	0.03	-0.23	0.61	0.24	0.11	-0.22	0.13	-0.54	0.41	0.32	-0.29
Cash	0.77	-0.62	0.58	0.61	0.48	-0.98	-0.61	0.36		0.78	0.55	0.62	0.53	0.52	0.75	0.77	0.47	0.67	0.35	0.24	0.57	-0.32	-0.74	0.71	0.67	0.48
Cash And Short Term Investments	1.0	-0.5	0.95	0.96	0.9	-0.8	-0.91	0.04	0.78		0.94	0.09	0.94	0.93	0.28	1.0	0.91	0.69	0.6	0.53	0.94	-0.75	-0.78	0.79	0.82	0.91
Common Stock Shares Outstanding	0.95	-0.31	0.99	0.98	0.98	-0.57	-0.93	-0.13	0.55	0.94		-0.21	1.0	1.0	-0.02	0.95	0.99	0.62	0.7	0.68	0.99	-0.8	-0.7	0.75	0.81	0.98
Non Current Liabilities Total	0.08	-0.54	-0.16	-0.09	-0.33	-0.63	0.04	0.76	0.62	0.09	-0.21		-0.23	-0.25	0.97	0.07	-0.32	0.4	-0.13	-0.27	-0.23	0.19	-0.39	0.24	0.14	-0.33
Other Current Assets	0.94	-0.31	1.0	0.99	0.98	-0.55	-0.94	-0.11	0.53	0.94	1.0	-0.23		1.0	-0.03	0.94	0.99	0.63	0.72	0.7	0.98	-0.79	-0.69	0.76	0.82	0.98
Other Stockholder Equity	0.94	-0.29	0.99	0.98	0.99	-0.54	-0.92	-0.18	0.52	0.93	1.0	-0.25	1.0		-0.06	0.94	1.0	0.58	0.69	0.68	0.99	-0.79	-0.66	0.73	0.79	0.99
Total Liab	0.27	-0.56	0.03	0.1	-0.15	-0.76	-0.15	0.76	0.75	0.28	-0.02	0.97	-0.03	-0.06		0.27	-0.13	0.55	0.03	-0.13	-0.04	0.04	-0.55	0.41	0.32	-0.15
Total Current Assets	1.0	-0.49	0.96	0.96	0.91	-0.79	-0.91	0.03	0.77	1.0	0.95	0.07	0.94	0.94	0.27		0.92	0.69	0.6	0.54	0.95	-0.75	-0.77	0.79	0.82	0.91
Common Stock	0.92	-0.25	0.98	0.96	0.99	-0.49	-0.9	-0.23	0.47	0.91	0.99	-0.32	0.99	1.0	-0.13	0.92		0.54	0.68	0.68	0.99	-0.8	-0.62	0.69	0.76	1.0
Property Plant And Equipment Net	0.69	-0.4	0.68	0.73	0.48	-0.66	-0.79	0.61	0.67	0.69	0.62	0.4	0.63	0.58	0.55	0.69	0.54		0.83	0.72	0.52	-0.4	-0.94	0.96	0.93	0.48
Non Current Assets Total	0.61	-0.11	0.74	0.76	0.62	-0.29	-0.82	0.24	0.35	0.6	0.7	-0.13	0.72	0.69	0.03	0.6	0.68	0.83		0.99	0.59	-0.36	-0.73	0.9	0.92	0.62
Non Currrent Assets Other	0.55	-0.02	0.71	0.72	0.63	-0.16	-0.78	0.11	0.24	0.53	0.68	-0.27	0.7	0.68	-0.13	0.54	0.68	0.72	0.99		0.58	-0.32	-0.62	0.83	0.86	0.63
Short Term Investments	0.95	-0.32	0.97	0.95	0.99	-0.58	-0.88	-0.22	0.57	0.94	0.99	-0.23	0.98	0.99	-0.04	0.95	0.99	0.52	0.59	0.58		-0.79	-0.63	0.67	0.73	0.99
Other Liab	-0.75	0.25	-0.79	-0.78	-0.78	0.39	0.63	0.13	-0.32	-0.75	-0.8	0.19	-0.79	-0.79	0.04	-0.75	-0.8	-0.4	-0.36	-0.32	-0.79		0.47	-0.42	-0.49	-0.78
Net Tangible Assets	-0.78	0.46	-0.74	-0.79	-0.57	0.76	0.83	-0.54	-0.74	-0.78	-0.7	-0.39	-0.69	-0.66	-0.55	-0.77	-0.62	-0.94	-0.73	-0.62	-0.63	0.47		-0.91	-0.87	-0.57
Current Deferred Revenue	0.79	-0.38	0.8	0.83	0.65	-0.67	-0.89	0.41	0.71	0.79	0.75	0.24	0.76	0.73	0.41	0.79	0.69	0.96	0.9	0.83	0.67	-0.42	-0.91		0.99	0.65
Capital Lease Obligations	0.83	-0.35	0.85	0.88	0.72	-0.63	-0.92	0.32	0.67	0.82	0.81	0.14	0.82	0.79	0.32	0.82	0.76	0.93	0.92	0.86	0.73	-0.49	-0.87	0.99		0.72
Net Invested Capital	0.91	-0.25	0.97	0.94	1.0	-0.49	-0.88	-0.29	0.48	0.91	0.98	-0.33	0.98	0.99	-0.15	0.91	1.0	0.48	0.62	0.63	0.99	-0.78	-0.57	0.65	0.72

Click cells to compare fundamentals

Enliven Therapeutics Account Relationship Matchups

Enliven Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	131.0M	113.3M	83.3M	271.9M	312.6M	328.3M
Other Current Liab	565K	3.1M	6.0M	25.0M	28.8M	30.2M
Total Current Liabilities	1.5M	5.8M	9.7M	25.9M	29.8M	31.3M
Total Stockholder Equity	(20.3M)	(42.9M)	(76.8M)	245.9M	282.8M	296.9M
Net Debt	(130.3M)	(109.9M)	(75.2M)	(99.8M)	(89.8M)	(94.3M)
Retained Earnings	(20.5M)	(45.2M)	(82.9M)	(154.4M)	(139.0M)	(132.1M)
Accounts Payable	808K	2.5M	3.4M	532K	611.8K	581.2K
Cash	130.4M	110.0M	75.5M	100.1M	115.2M	68.8M
Cash And Short Term Investments	130.4M	110.0M	75.5M	253.1M	291.1M	305.7M
Common Stock Shares Outstanding	3.5M	7.8M	6.2M	35.5M	40.9M	42.9M
Liabilities And Stockholders Equity	131.0M	113.3M	83.3M	271.9M	312.6M	328.3M
Non Current Liabilities Total	149.8M	150.5M	150.4M	67K	77.1K	73.2K
Other Current Assets	222K	646K	2.2M	13.0M	15.0M	15.7M
Other Stockholder Equity	157K	2.3M	6.2M	400.2M	460.2M	483.2M
Total Liab	151.3M	156.2M	160.1M	26.0M	29.9M	28.4M
Total Current Assets	130.6M	110.7M	77.8M	266.2M	306.1M	321.4M
Property Plant And Equipment Net	416K	954K	1.5M	1.1M	1.2M	965.8K
Non Current Assets Total	416K	2.7M	5.5M	5.7M	6.6M	3.7M
Non Currrent Assets Other	(88K)	1.5M	4.0M	4.7M	5.4M	2.7M
Short Term Investments	40.5M	42.0M	0.0	153.0M	176.0M	184.8M
Accumulated Other Comprehensive Income	4K	(16K)	(149.7K)	141K	162.2K	170.3K

When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock:

How To Invest In Enliven

Details

Is Enliven Stock a good investment?

Details

What is Enliven Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.89)

Return On Assets

(0.21)

Return On Equity

(0.31)

The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enliven Common Stock Shares Outstanding vs Current Deferred Revenue Analysis

Common Stock Shares Outstanding vs Current Deferred Revenue

Common Stock Shares Outstanding vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Common Stock Shares Outstanding

Current Deferred Revenue

Enliven Therapeutics fundamental ratios Correlations

Enliven Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enliven Therapeutics fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Other Current Assets	+ 1.0	Other Current Liab
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 0.98	Net Debt
Retained Earnings	- 0.97	Total Current Liabilities
Retained Earnings	- 0.96	Other Current Liab
Net Tangible Assets	- 0.94	Property Plant And Equipment Net
Other Current Assets	- 0.94	Retained Earnings
Common Stock Shares Outstanding	- 0.93	Retained Earnings